The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease
Open accessAbstract
OBJECTIVE: Assess Aβ deposition longitudinally and explore its relationship with cognition and disease progression. METHODS: Clinical follow-up was obtained 20 ± 3 months after [¹¹C]Pittsburgh compound B (PiB)-positron emission tomography in 206 subjects: 35 with dementia of the Alzheimer type (DAT), 65 with mild cognitive impairment (MCI), and 106 age-matched healthy controls (HCs). A second PiB scan was obtained at follow-up in 185 subjects and a third scan after 3 years in 57. RESULTS: At baseline, 97% of DAT, 69% of MCI, and 31% of HC subjects showed high PiB retention. At 20-month follow-up, small but significant increases in PiB standardized uptake value ratios were observed in the DAT and MCI groups, and in HCs with high PiB retention at baseline (5.7%, 2.1%, and 1.5%, respectively). Increases were associated with the number of apolipoprotein E ε4 alleles. There was a weak correlation between PiB increases and decline in cognition when all groups were combined. Progression to DAT occurred in 67% of MCI with high PiB versus 5% of those with low PiB, but 20% of the low PiB MCI subjects progressed to other dementias. Of the high PiB HCs, 16% developed MCI or DAT by 20 months and 25% by 3 years. One low PiB HC developed MCI. INTERPRETATION: Aβ deposition increases slowly from cognitive normality to moderate severity DAT. Extensive Aβ deposition precedes cognitive impairment, and is associated with ApoE genotype and a higher risk of cognitive decline in HCs and progression from MCI to DAT over 1 to 2 years. However, cognitive decline is only weakly related to change in Aβ burden, suggesting that downstream factors have a more direct effect on symptom progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and that progression of biomarker measures is also a continuous process that begins before symptoms [9–14]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have shown that CU individuals with abnormal amyloid biomarkers have more rapid progression of atrophy, hypometabolism, and clinical/cognitive decline than individuals without biomarker evidence of Aβ deposition [13,33,80,93–99]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ε4 allele increased brain amyloid burden in a dose-dependent manner in normal elderly individuals and in mild cognitive impairment patients [93,94].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a study characterizing sporadic AD, for instance, Villemagne et al. used Pittsburgh compound B (PiB) positron emission tomography (PET) to show that 31% of healthy control subjects had high PiB retention indicating Aß deposition and of these, 25% developed mild cognitive impairment or AD by 3 years (Villemagne et al., 2011).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Villemagne et al., 2011
In the citing paper
“Previous longitudinal studies have either failed to detect an early increase in regional Aβ deposition16 or identified a rather large early stage Aβ region including the posterior temporal, inferior parietal, posterior cingulate, precuneus, and occipital areas4.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N., Mazoyer, B., & Joliot, M. (2002) · NeuroImage · doi:10.1006/nimg.2001.0978 · Cited by 16,319
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Self-citationVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Design and construction of a realistic digital brain phantom
Collins, D. L., Zijdenbos, A. P., Kollokian, V., Sled, J. G., Kabani, N. J., Holmes, C. J., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.712135 · Cited by 1,825
Mitchell, A. J., & Shiri‐Feshki, M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01326.x · Cited by 1,659
Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline
Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268
Imaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Self-citationJack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 836
Emerging Biomarkers in Cognition
Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 17
Ellis, K. A., Rainey‐Smith, S. R., Rembach, A., Macaulay, S. L., Villemagne, V. L., & Aibl research group (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.870136 · Cited by 17
Self-citationEmpirically Defining Trajectories of Late-Life Cognitive and Functional Decline
Hochstetler, H. M., Initiative, A. D. N., Trzepacz, P. T., Wang, S., Yu, P., Case, M. G., Henley, D. B., Degenhardt, E. K., Leoutsakos, J., & Lyketsos, C. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150563 · Cited by 17
East, B. S., Fleming, G., Peng, K., Olofsson, J., Levy, E., Mathews, P. M., & Wilson, D. A. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.04.009 · Cited by 20
Ba, M., Ng, K. P., Gao, X., Kong, M., Guan, L., Yu, L., & Initiative, T. A. D. N. (2018) · European Journal of Neurology · doi:10.1111/ene.13881 · Cited by 16
Deep residual inception encoder‐decoder network for amyloid PET harmonization
Shah, J., Gao, F., Li, B., Ghisays, V., Luo, J., Chen, Y., Lee, W., Zhou, Y., Benzinger, T. L. S., Reiman, E. M., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12564 · Cited by 16
In vivo cortical diffusion imaging relates to Alzheimer's disease neuropathology
Torso, M., Ridgway, G. R., Valotti, M., Hardingham, I., Chance, S. A., for the National Alzheimer’s Coordinating Center, Brewer, J., Lopez, O., Hyman, B., Grabowski, T., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01309-3 · Cited by 16
Longitudinal Amyloid-β PET in Atypical Alzheimer’s Disease and Frontotemporal Lobar Degeneration
Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Duffy, J. R., Clark, H. M., Machulda, M. M., Botha, H., Utianski, R. L., Schwarz, C. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190699 · Cited by 16
Diffusion Changes in Hippocampal Cingulum in Early Biologically Defined Alzheimer’s Disease
Chen, Q., Initiative, A. D. N., Abrigo, J., Deng, M., Shi, L., Wáng, Y. X. J., & Chu, C. W. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220671 · Cited by 16
Identifying healthy individuals with Alzheimer’s disease neuroimaging phenotypes in the UK Biobank
Azevedo, T., Bethlehem, R. A. I., Whiteside, D. J., Swaddiwudhipong, N., Rowe, J. B., Lió, P., Rittman, T., Initiative, T. A. D. N., Silbert, L. C., Lind, B., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00313-w · Cited by 17
The temporal event-based model: Learning event timelines in progressive diseases
Wijeratne, P. A., Eshaghi, A., Scotton, W. J., Kohli, M., Aksman, L., Oxtoby, N. P., Pustina, D., Warner, J. H., Paulsen, J. S., Scahill, R. I., et al. (2023) · Imaging Neuroscience · doi:10.1162/imag_a_00010 · Cited by 20
Shanks, H. R. C., Onuska, K. M., Massa, S. M., Schmitz, T. W., & Longo, F. M. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.110 · Cited by 17
Deng, J., Wang, H., Fu, T., Xu, C., Zhu, Q., Guo, L., & Zhu, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1365589 · Cited by 17
Molecular Brain Imaging in the Multimodality Era
Price, J. C. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.29 · Cited by 16
Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses
Huang, Y., Hong, X., Shen, J. X., Geng, L.-J., Pan, Y.-H., Ling, W., & Zhao, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02980 · Cited by 16
Treyer, V., Meyer, R., Buchmann, A., Crameri, G. A. G., Studer, S. T., Saake, A., Gruber, E., Unschuld, P. G., Nitsch, R. M., Höck, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247225 · Cited by 18
Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models
Gurdon, B., & Kaczorowski, C. C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105558 · Cited by 16
Brier, M. R., McCarthy, J. E., Benzinger, T. L. S., Stern, A., Su, Y., Friedrichsen, K. A., Morris, J. C., Ances, B. M., & Vlassenko, A. G. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.025 · Cited by 16
Lin, R.-R., Xue, Y., Li, X., Chen, Y.-H., Tao, Q., & Wu, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.718959 · Cited by 15
Wang, J., Wang, M., Ren, S., Huang, L., He, K., Li, J., Hua, F., Guan, Y., Guo, Q., Huang, Q., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221166 · Cited by 15
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough
McEvoy, L. K., & Brewer, J. B. (2012) · Imaging in Medicine · doi:10.2217/iim.12.27 · Cited by 15
Challenges in the Neuropathological Diagnosis of Dementias
Jellinger, K. A. (2012) · International Journal of Neuropathology · doi:10.7726/ijn.2013.1002 · Cited by 15
Risk factors for amyloid positivity in older people reporting significant memory concern
Zhang, J., Zhou, W., Cassidy, R. M., Su, H., Su, Y., & Zhang, X. (2017) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2017.09.015 · Cited by 17
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16
Hahn, A., Kim, Y. J., Kim, H. J., Jang, H., Cho, H., Choi, S. H., Kim, B. C., Park, K. W., Na, D. L., Chin, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70386-3 · Cited by 17
The Israel Registry for Alzheimer’s Prevention (IRAP) Study: Design and Baseline Characteristics
Ravona‐Springer, R., Sharvit‐Ginon, I., Ganmore, I., Greenbaum, L., Bendlin, B. B., Sternberg, S. A., Livny, A., Domachevsky, L., Sandler, I., Ben‐Haim, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200623 · Cited by 16
Snellman, A., Ekblad, L. L., Koivumäki, M., Lindgrén, N., Tuisku, J., Perälä, M., Kallio, L., Lehtonen, R., Saunavaara, V., Saunavaara, J. P., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.826423 · Cited by 15
Palmomental Reflex a Relevant Sign in Early Alzheimer’s Disease Diagnosis?
Gabelle, A., Gutierrez, L., Dartigues, J., Ritchie, K. A., Touchon, J., & Berr, C. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150436 · Cited by 16
Lancaster, C. L., Tabet, N., & Rusted, J. M. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.015 · Cited by 16
Pedrini, S., Hone, E., Gupta, V. B., JAMES, I. R., Teimouri, E., Bush, A. I., Rowe, C. C., Villemagne, V. L., Ames, D. J., Masters, C. L., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200291 · Cited by 16
Self-citationFlorbetapir F 18 for brain imaging of beta-amyloid plaques
Romano, M., & Buratti, E. (2013) · Drugs of today · doi:10.1358/dot.2013.49.3.1937428 · Cited by 15
Su, H., Masters, C. L., Bush, A. I., Barnham, K. J., Reid, G. E., & Vella, L. J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300063 · Cited by 13
Self-citationBiomarcadores en la enfermedad de Alzheimer
Ribas, G. G., López-Sendón, J. L., & Caldentey, J. G. (2014) · Revista de Neurología · doi:10.33588/rn.5807.2013394 · Cited by 14
Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB‐PET Threshold
Ismail, R., Parbo, P., Hansen, K. V., Schaldemose, J. L., Dalby, R. B., Tietze, A., Kjeldsen, P. L., la Cour, S. H., Qvist, P., Gottrup, H., et al. (2019) · Journal of Neuroimaging · doi:10.1111/jon.12629 · Cited by 14
Volloch, V., & Rits‐Volloch, S. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220031 · Cited by 15
Tu, Y., Chai, K., Wu, J., Hu, Y., Shi, S., Yang, D., & Yao, T. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.133406 · Cited by 14
Coliva, A., Monterisi, C., Apollaro, A., Gatti, D., Penso, M., Gianolli, L., Perani, D., Gilardi, M. C., & Carpinelli, A. (2015) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2015.07.003 · Cited by 14
Age‐related modulation of γ‐secretase activity in non‐human primate brains
Nishimura, M., Nakamura, S., Kimura, N., Liu, L., Suzuki, T., & Tooyama, I. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07884.x · Cited by 14
Initiative, A. D. N., Chiotis, K., Carter, S. F., Farid, K., Savitcheva, I., & Nordberg, A. K. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3115-5 · Cited by 16
Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques
Hayne, D. J., White, J. M., McLean, C., Villemagne, V. L., Barnham, K. J., & Donnelly, P. S. (2016) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6b00972 · Cited by 14
Self-citationAssociations of Neprilysin Activity in CSF with Biomarkers for Alzheimer’s Disease
Grimmer, T., Goldhardt, O., Yakushev, I., Ortner, M., Sorg, C., Diehl-Schmid, J., Förstl, H., Kurz, A., Perneczky, R., & Miners, S. (2019) · Neurodegenerative Diseases · doi:10.1159/000500811 · Cited by 13
Amyloid-β PET Classification on Cognitive Aging Stages Using the Centiloid Scale
de Souza, G. S., Andrade, M. A., Borelli, W. V., Schilling, L. P., Matushita, C. S., Portuguez, M. W., da Costa, J. C., & da Silva, A. M. M. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01660-7 · Cited by 16
Patterns of Early Neocortical Amyloid-β Accumulation: A PET Population-Based Study
Lecy, E., Min, H.-K. P., Apgar, C. J., Maltais, D. D., Lundt, E. S., Albertson, S. M., Senjem, M. L., Schwarz, C. G., Botha, H., Graff‐Radford, J., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.267150 · Cited by 18
Booij, J., Arbizu, J., Darcourt, J., Hesse, S., Nobili, F. M., Payoux, P., Pappatà, S., Tatsch, K., Walker, Z., & Pagani, M. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2415-x · Cited by 13
Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
Chen, Y., Ma, X., Sundell, K. L., Alaka, K., Schuh, K. J., Raskin, J., & Dean, R. A. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.005 · Cited by 13
Jing, J., Zhang, F., Zhao, L., Xie, J., Chen, J., Zhong, R., Zhang, Y., & Dong, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201335 · Cited by 13
Biomarkers for the early diagnosis of Alzheimer's disease: The challenge of XXI century
Contino, M., Cantore, M., Leopoldo, M., & Colabufo, N. (2013) · Advances in Alzheimer s Disease · doi:10.4236/aad.2013.21003 · Cited by 16
Amyloid burden correlates with cognitive decline in A lzheimer's disease presenting with aphasia
Jung, Y., Whitwell, J. L., Duffy, J. R., Strand, E. A., Machulda, M. M., Senjem, M. L., Lowe, V. J., Jack, C. R., & Josephs, K. A. (2013) · European Journal of Neurology · doi:10.1111/ene.12331 · Cited by 13
Cardenas, V. A., Tosun, D., Chao, L. L., Fletcher, P. T., Joshi, S. C., Weiner, M. W., & Schuff, N. W. (2013) · Journal of Neuroimaging · doi:10.1111/jon.12002 · Cited by 13
Ho, K., Toh, C., Li, S., Liu, C., Yang, C., Lin, Y.-J., Su, T.-P., Wang, C., & Yen, T. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4210-1 · Cited by 13
Schaeverbeke, J. M., Gille, B., Adamczuk, K., Vanderstichele, H., Chassaing, E., Bruffaerts, R., Neyens, V., Stoops, E., Tournoy, J., Vandenberghe, R. R., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14680 · Cited by 13
Chang, Y. Z., Li, C., Yang, H., Wu, Y., Xu, B., Zhang, J., & Wang, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00745 · Cited by 14
Amyloid burden quantification depends on PET and MR image processing methodology
Kolinger, G. D., García, D. V., Willemsen, A. T. M., Reesink, F. E., de Jong, B. M., Dierckx, R., Deyn, P. P. D., & Boellaard, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248122 · Cited by 13
Learning deficit in cognitively normal APOE ε4 carriers with LOW β‐amyloid
Lim, Y. Y., Baker, J. E., Mills, A., Bruns, L., Fowler, C. J., Fripp, J., Rainey‐Smith, S. R., Ames, D. J., Masters, C. L., & Maruff, P. T. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12136 · Cited by 13
Self-citationUquillas, F. D., Jacobs, H. I. L., Hanseeuw, B. J., Marshall, G. A., Properzi, M. J., Schultz, A. P., LaPoint, M. R., Johnson, K. A., Sperling, R. A., & Vannini, P. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.10.034 · Cited by 14
Rullmann, M., McLeod, A., Grothe, M. J., Sabri, O., & Barthel, H. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.238477 · Cited by 12
Volloch, V., & Rits‐Volloch, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417586 · Cited by 13
Technical aspects of amyloid imaging for Alzheimer's disease
Edison, P., Hinz, R., & Brooks, D. J. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt87 · Cited by 12
Chang, Y. Z., Liu, J., Wang, L. Y., Li, X., Wang, Z., Lin, M., Jin, W., Zhu, M., & Xu, B. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.721780 · Cited by 13
Moallemian, S., Salmon, É., Bahri, M. A., Beliy, N., Delhaye, E., Balteau, E., Degueldre, C., Phillips, C. L. M., & Bastin, C. (2023) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2023.08.001 · Cited by 16
Quenon, L., Dricot, L., Woodard, J. L., Hanseeuw, B. J., Gilis, N., Lhommel, R., & Ivanoiu, A. (2016) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617716000813 · Cited by 12
Subcortical amyloid load is associated with shape and volume in cognitively normal individuals
Rahayel, S., Bocti, C., Sévigny-Dupont, P., Joannette, M., Lavallée, M. M., Nikelski, J., Chertkow, H. M., & Joubert, S. (2019) · Human Brain Mapping · doi:10.1002/hbm.24680 · Cited by 11
Calderón‐Garcidueñas, L., Chávez, V. S. J., Vacaseydel-Aceves, N., Calderón-Sánchez, R., Escobedo, E. H. M., Frías, C., Giacometto, M., Velásquez, L., Félix-Villarreal, R., Martin, J. D., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00232 · Cited by 12
Wang, W., Myers, S. J., Ollen‐Bittle, N., & Whitehead, S. N. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106798 · Cited by 12
Kurowska, E., Ruciński, J., Myślińska, D., Grembecka, B., Wrona, D., & Majkutewicz, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415449 · Cited by 12
Amyloid-β accumulation in relation to functional connectivity in aging: A longitudinal study
Liu, G., Shen, C., & Qiu, A. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120146 · Cited by 14
Structural imaging in early pre-states of dementia
Smith, C. D. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.002 · Cited by 11
Immune modulations and immunotherapies for Alzheimer’s disease: a comprehensive review
Mahdiabadi, S., Momtazmanesh, S., Perry, G. L., & Rezaei, N. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0092 · Cited by 13
Independent effect of body mass index variation on amyloid-β positivity
Kang, S. H., Kim, J. H., Chang, Y., Cheon, B. K., Choe, Y. S., Jang, H., Kim, H. J., Koh, S., Na, D. L., Kim, K., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.924550 · Cited by 11
Amyloid imaging in Alzheimer's disease: A literature review
Saidlitz, P., Voisin, T., Vellas, B. J., Payoux, P., Gabelle, A., Formaglio, M., & Delrieu, J. (2014) · The journal of nutrition health & aging · doi:10.1007/s12603-014-0507-3 · Cited by 12
Arbizu, J., García‐Ribas, G., Carrió, I., Garrastachu, P., Martínez‐Lage, P., & Molinuevo, J. L. (2015) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2015.05.004 · Cited by 11
Nadkarni, N. K., Tudorascu, D., Campbell, E., Snitz, B. E., Cohen, A. D., Halligan, E., Mathis, C. A., Aizenstein, H. J., & Klunk, W. E. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz088 · Cited by 11
Self-citationFischer, L., Parker, D. M., Maboudian, S. A., Fonseca, C. S., Tato-Fernández, C., Annen, L., Arunachalam, P., Bacci, J. R., Barboure, M. C., Capelli, S., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01920-6 · Cited by 13
[18F]-florbetaben PET/CT Imaging in the Alzheimer’s Disease Mouse Model APPswe/PS1dE9
Stenzel, J., Rühlmann, C., Lindner, T., Polei, S., Teipel, S. J., Kurth, J., Rominger, A., Krause, B. J., Vollmar, B., & Kuhla, A. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181022095904 · Cited by 11
Current Conceptual View of Alzheimer’s Disease
Herrup, K. (2012) · Advances in biological psychiatry · doi:10.1159/000335378 · Cited by 10
Disease‐modifying therapy for Alzheimer's disease: Challenges and hopes
Iwata, A., & Iwatsubo, T. (2013) · Neurology and Clinical Neuroscience · doi:10.1002/ncn3.20 · Cited by 10
Molecular neuroimaging in degenerative dementias
Jiménez-Bonilla, J. F., & CARRIL, J. M. (2013) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2013.07.027 · Cited by 10
Hatashita, S., & Wakebe, D. (2019) · Future Science OA · doi:10.4155/fsoa-2018-0069 · Cited by 10
Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study
Initiative, J. A. D. N., Okada, Y., Kato, T., Iwata, K., Kimura, Y., Nakamura, A., Hattori, H., Toyama, H., Ishii, K., Ishii, K., et al. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01420-2 · Cited by 11
PET Imaging of brain muscarinic receptors with 18F-Fluorobenzyl-Dexetimide: A first in human study
Rowe, C. C., Krishnadas, N., Ackermann, U., Doré, V., Goh, R., Guzman, R., Chong, L., Bozinovski, S., Mulligan, R. S., Kanaan, R., et al. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111354 · Cited by 10
Self-citationSur, C., Adamczuk, K., Scott, D., Kost, J. T., Sampat, M. P., Buckley, C. J., Farrar, G., Newton, B., Suhy, J., Bennacef, I., et al. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01735-z · Cited by 10
Imago Mundi, Imago AD, Imago ADNI
Villemagne, V. L., Kim, S. Y., Rowe, C. C., & Iwatsubo, T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0062-5 · Cited by 10
Self-citationJagust, W. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.152 · Cited by 10
Furst, A. J., & Kerchner, G. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182662084 · Cited by 10
Chattopadhyay, T., Ozarkar, S. S., Buwa, K., Thomopoulos, S. I., Thompson, P. M., & Initiative, T. A. D. N. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528705 · Cited by 11
Two decades of [11C]PiB synthesis, 2003-2023: a review
Myburgh, P. J. (2024) · American Journal of Nuclear Medicine and Molecular Imaging · doi:10.62347/adsk6584 · Cited by 12
Advanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer’s Disease
Sepulcre, J., & Masdeu, J. C. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_31 · Cited by 9
Rami, L., León, M., Valech, N., Coll‐Padrós, N., Bosch, B., Olives, J., Salinero, A., Pérez‐Millan, A., Molinuevo, J. L., Sánchez‐Valle, R., et al. (2023) · Neuropsychology · doi:10.1037/neu0000879 · Cited by 9
Ta, M., Blauwendraat, C., Antar, T., Leonard, H. L., Singleton, A., Nalls, M. A., Iwaki, H., Initiative, A. D. N., & Biomarkers, T. F. I. F. N. D. O. (2023) · Movement Disorders · doi:10.1002/mds.29511 · Cited by 9
The current state of apolipoprotein E in dyslipidemia
Rasmussen, K. L., & Frikke‐Schmidt, R. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000915 · Cited by 11
Franco, R., Garrigós, C., Lillo, J., & Rivas‐Santisteban, R. (2024) · Cells · doi:10.3390/cells13151288 · Cited by 9
Mukhamedyarov, M. A., Rizvanov, A. A., Yakupov, E. Z., Zefirov, A. L., Kiyasov, A. P., Reis, H. J., Teixeira, A. L., Vieira, L. B., Lima, L. M., Salafutdinov, I. I., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160457 · Cited by 9
Ubukata, S., Oishi, N., Higashi, T., Kagawa, S., Yamauchi, H., Okuyama, C., Watanabe, H., Ono, M., Saji, H., Aso, T., et al. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s268504 · Cited by 9
Sensitive Measures of Cognition in Mild Cognitive Impairment
Klooster, N. B., Humphries, S. A., Cardillo, E. R., Hartung, F., Xie, L., Das, S. R., Yushkevich, P. A., Pilania, A., Wang, J., Wolk, D. A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201280 · Cited by 9
Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology to Treatment Target
Liu, H., Leu, S., & Chuang, D. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.04.001 · Cited by 9
Adriaanse, S. M., Dijk, K. R. A. V., Ossenkoppele, R., Reuter, M., Tolboom, N., Zwan, M. D., Yaqub, M. M., Boellaard, R., Windhorst, A. D., van der Flier, W. M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2704-z · Cited by 9
Amyloid deposition in semantic dementia: a positron emission tomography study
Brown, E. E., Graff‐Guerrero, A., Houle, S., Mizrahi, R., Wilson, A. A., Pollock, B. G., Mulsant, B. H., Felsky, D., Voineskos, A. N., Tang‐Wai, D. F., et al. (2016) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4423 · Cited by 9
Hammes, J., Bischof, G. N., & Drzezga, A. E. (2017) · Clinical and Translational Imaging · doi:10.1007/s40336-017-0242-y · Cited by 9
Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimer’s Disease
Venkatraman, V. K., Steward, C. E., Cox, K. L., Ellis, K. A., Phal, P. M., Sharman, M. J., Villemagne, V. L., Lai, M. M. Y., Cyarto, E., Ames, D. J., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00115 · Cited by 9
Self-citationOn the Inadequacy of the Current Transgenic Animal Models of Alzheimer’s Disease: The Path Forward
Volloch, V., & Rits‐Volloch, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052981 · Cited by 9
Metadata
- Authors
- Villemagne, V. L., Pike, K. E., Chételat, G., Ellis, K. A., Mulligan, R. S., Bourgeat, P., Ackermann, U., Jones, G., Szoeke, C., Salvado, O., Martins, R., O'Keefe, G., Mathis, C. A., Klunk, W. E., Ames, D., Masters, C. L., & Rowe, C. C.
- Affiliations
- Mental Health Research Institute (AU)
- Austin Health (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Australian e-Health Research Centre (AU)
- Edith Cowan University (AU)
- University of Pittsburgh (US)
- National Ageing Research Institute (AU)
- The University of Melbourne (AU)
- Corresponding author
- Villemagne, Victor L.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 69
- Issue
- 1
- Pages
- 181-192
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3045039
- OpenAlex
- W2051489981
- Cited by
- 833
- References
- 42
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 26 · 2023: 51 · 2022: 42 · 2021: 44 · 2020: 57 · 2019: 60 · 2018: 57 · 2017: 57 · 2016: 60 · 2015: 61 · 2014: 68 · 2013: 86 · 2012: 71
- FWCI
- 57.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- Funders
- National Institute on Aging (P01AG025204, RF1AG025516, P50AG005133, R37AG025516)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- amyloid-beta deposition, Alzheimer's disease, mild cognitive impairment, Pittsburgh compound B PET, APOE ε4, cognitive decline, disease progression, aging
- MeSH terms
- Aged, Aging, Alzheimer Disease, Aniline Compounds, Brain, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Neuropsychological Tests, Polymorphism, Genetic, Severity of Illness Index, Thiazoles, Amyloid beta-Peptides, Disease Progression, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
